Retrospective Cohort Study Comparing Infliximab-dyyb and Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease in the United States.

Smith, Joshua T; Velayos, Fernando S; Niu, Fang; Liu, Vincent; Delate, Thomas; Pola, Suresh; Le, Kim; Hui, Rita L

Smith, Joshua T; Velayos, Fernando S; Niu, Fang; Liu, Vincent; Delate, Thomas; Pola, Suresh; Le, Kim; Hui, Rita L.

Afiliação

Smith JT; Division of Research, Kaiser Permanente Northern California, Oakland, California, USA.
Velayos FS; Division of Gastroenterology and Hepatology, The Permanente Medical Group, San Francisco, California, USA.
Niu F; Kaiser Permanente National Pharmacy, Pharmacy Outcomes Research Group, National Pharmacy Services, Downey, California, USA.
Liu V; Division of Research, Kaiser Permanente National Pharmacy, Oakland, California, USA.
Delate T; Pharmacy Outcomes Research Group, National Pharmacy Services, Aurora, Colorado, USA.
Pola S; Kaiser Permanente National Pharmacy, Department of Gastroenterology, Southern California Permanente Medical Group, San Diego, California, USA.
Le K; Kaiser Permanente National Pharmacy, Drug Evaluation, Strategy and Outcomes, National Pharmacy Services, Kaiser Permanente National Pharmacy, Downey, California, USA.
Hui RL; Kaiser Permanente National Pharmacy, Pharmacy Outcomes Research Group, National Pharmacy Services, Oakland, California, USA.

Crohns Colitis 360 ; 3(3): otab051, 2021 Jul.

Article em En | MEDLINE | ID: mdl-36776661

Palavras-chave

biosimilar; inflammatory bowel disease; infliximb-dyyb

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Idioma: En Revista: Crohns Colitis 360 Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google